COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Effect of Monosodium L-Glutamate (MSG) and Nucleic Acid (IMP) on Satiety and Food Intake

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01761045
Recruitment Status : Completed
First Posted : January 4, 2013
Last Update Posted : February 11, 2013
Information provided by (Responsible Party):
Ajinomoto Co., Inc.

Brief Summary:
The objective of this study is to confirm that Monosodium L-Glutamate (MSG) supplementation, both alone or in combination with Nucleic Acid (IMP), enhances satiety and decreases food intakes at the next meal in healthy female adults.

Condition or disease Intervention/treatment Phase
Nutrition Intervention Dietary Supplement: Soup 1 Dietary Supplement: Soup 2 Dietary Supplement: Soup 3 Not Applicable

Detailed Description:

The study is a randomized, double-blind, placebo-controlled, cross-over clinical trial. A total of 80 women aged 30 to 45 y will be randomized to a sequence of test product administration.

Subjects will be required to meet several inclusion and exclusion criteria, which will be assessed at the screening visit, including a general screening questionnaire, medical/medication history, eating disorder questionnaire, eating inventory questionnaire, dietary inventory questionnaire, and anthropometric and vital sign measurements. At the screening visit, a urine sample will be collected for drug and alcohol screening, cotinine level, and pregnancy. Alcohol breath test will be performed as well.

After assessment of the eligibility criteria, qualified subjects will be invited to participate in the study. This study will take approximately 3 weeks to complete.

Subjects will return to the study site within 28 days after the screening visit for testing period 1, followed by 2 additional visits (testing period 2 and 3).

Subjects will consume 1 of 3 treatments, based on randomization sequence at each test period visit: Consommé soup with Monosodium L-Glutamate (MSG), Consommé soup with MSG and Nucleic Acid (IMP), and Placebo soup with no MSG or IMP.

When subjects arrive at the research center at approximately 11:30am, admission procedures will be conducted: an alcohol breath test, food and activity diary review, and vital signs and weight will be measured. If vital sign measurements are elevated, subjects will be rescheduled within 2-3 days. Right before serving the standard lunch meal, subjects will be asked to complete a satiety motivational questionnaire. Subjects will consume the entire standard lunch meal and water within 30 min. Immediately after eating the standard lunch meal, subjects will complete the satiety motivational questionnaire.

Two hours after the standard lunch meal, subjects will be given one of the test soups (based on their randomization) to consume in its entirety, followed by completion of the satiety motivational questionnaire and the soup rating questionnaire. Fifteen minutes from test soup administration, snacks and water (ad lib) will be provided and subjects will be instructed to eat as much as or as little as they desire, followed by completing the satiety motivational questionnaire. At 3 h 15 min and at 4 h, subjects will complete the satiety motivational questionnaire.

Test periods 2 and 3 will be scheduled between 3-14 days after completing test period visit 1: all procedures are identical on each test period visit with the exception of the test treatment soup consumed by subjects.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Crossover Clinical Study of Monosodium L-Glutamate (MSG) and Nucleic Acid (IMP) to Evaluate the Effects on Satiety and Food Intakes at the Next Meal in Healthy Adults
Study Start Date : July 2010
Actual Primary Completion Date : January 2011
Actual Study Completion Date : January 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: Soup 1
Consommé soup with Monosodium L-Glutamate (MSG)
Dietary Supplement: Soup 1
Consommé soup with Monosodium L-Glutamate (MSG)

Active Comparator: Soup 2
Consommé soup with Monosodium L-Glutamate (MSG) and Nucleic Acid (IMP)
Dietary Supplement: Soup 2
Consommé soup with Monosodium L-Glutamate (MSG) and Nucleic Acid (IMP)

Placebo Comparator: Soup 3
Placebo soup with no Monosodium L-Glutamate (MSG) or Nucleic Acid (IMP)
Dietary Supplement: Soup 3
Placebo soup with no Monosodium L-Glutamate (MSG) or Nucleic Acid (IMP)

Primary Outcome Measures :
  1. Differences in food intake and subjective satiety motivational responses to treatments [ Time Frame: 4-hr postprandial study ]

Secondary Outcome Measures :
  1. Correlation between genetic makeup of the subject and the primary efficacy endpoints. [ Time Frame: 3 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   30 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy Female, 30 to 45 yrs old
  • Non-smoker
  • Non-heavy Drinker
  • BMI between 18.5 and 25.0 inclusive at the screening visit

Exclusion Criteria:

  • History or presence of any serious and/or chronic medical or clinical disease, including renal disease, hepatic (biliary) disease, uncontrolled hypertension or uncontrolled thyroid disease, surgical conditions, cardiovascular disease other than mild hypertension or dyslipidemias, myocardial infarction, or other conditions that in the opinion of the investigator may increase the risk of participation or compromise/confound the study results
  • History or diagnosis of type 1 or 2 diabetes mellitus or other uncontrolled endocrine disease
  • Dysgeusia
  • Any history of gastrointestinal disease or currently on treatment for a digestive disease
  • Eating disorder or abnormal eating habits
  • Undergone a recent significant weight change (gain or loss)
  • Participating on a weight-loss program within the past 6 months prior to entry into the study
  • Taking any medications for the alimentary system
  • Allergy or sensitivity to foods or food additives
  • History of using habitual drugs and/or alcohol abuse within the past year
  • Psychosis and/or suffering from any other condition(s) which might render the individual unable to comply with the protocol or place subjects at increased risk at the discretion of the PI
  • Used any investigational drug or product within the 1 month prior to the screening visit
  • On special diet such as vegetarian
  • Dislike the preloading soup and/or the provided lunch and/or study snacks
  • Currently breast feeding and/or pregnant in the past 6 months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01761045

Layout table for location information
United States, New Jersey
IBERICA Clinical Research Center
Eatontown, New Jersey, United States, 07724
Sponsors and Collaborators
Ajinomoto Co., Inc.
Layout table for investigator information
Principal Investigator: Joel S Ross, MD The Memory Enhancement Center of America, Inc.
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Ajinomoto Co., Inc. Identifier: NCT01761045    
Other Study ID Numbers: AJU-S002
First Posted: January 4, 2013    Key Record Dates
Last Update Posted: February 11, 2013
Last Verified: February 2013
Keywords provided by Ajinomoto Co., Inc.:
Monosodium L-Glutamate (MSG)
Nucleic Acid (IMP)
Gastrointestinal Sensation
Consommé Soups
Snack Intake